Product Details:
Payment & Shipping Terms:
|
Purity: | 99% | Application: | Pharm Intermediates |
---|---|---|---|
Type: | Pharmaceutical Intermediates | Appearance: | White Powder |
Color: | White | Boiling Point: | 39.8-40 °C Mm Hg(lit.) |
Grade: | Pharmaceutcial Grade | ||
High Light: | active pharmaceutical ingredient,pharmaceutical raw materials |
Product Name:Choline Glycerophosphate
Alias:L-Alpha glycerylphosphorylcholine,Choline alfoscerate,alpha-GPC
CAS NO.:28319-77-9
EINECS:248-962-2
Molecular Formula:C8H20NO6P
Molecular Weight:257.22
Purity:98%
Grade:Food Grade
Appearance:White Powder
L-Alpha glycerylphosphorylcholine (alpha-GPC, choline alfoscerate) is a natural choline compound found in the brain. It is also a parasympathomimetic acetylcholine precursor which may have potential for the treatment of Alzheimer's disease and other dementias.
Alpha-glycerophosphocholine (Alpha-GPC or α-GPC) is a cholinergic compound that is used for its cognitive-promoting properties, and to enhance power output in athletes. It appears to also support cellular membranes, and may aid in preventing cognitive decline.
Alpha-GPC (Alpha-glycerophosphocholine or sometimes just glycerophosphocholine) is a Choline-containing supplement that, although found in a variety of food products that are also rich in choline, appears to be pharmacologically active at higher doses.
Alpha-GPC is mostly marketed due to it conferring dietary choline to the body following oral ingestion, and being the most efficient choline prodrug at doing so (able to influence both systemic and brain concentrations of choline). Due to the provision of the other half of the alpha-GPC molecule (glycerophosphate), alpha-GPC also appears to support the structure of cellular membranes, which is not a common mechanism attributed to choline prodrugs (only CDP-choline is associated with lipid membranes in this sense).
Oral supplementation of alpha-GPC is of interest for nootropic purposes, as it appears to have cognitive-enhancing properties (no human evidence exists to support this in otherwise-healthy youth, but it does have support in rodents) and attenuate the rate of cognitive decline in the elderly. In regards to reducing the rate of cognitive decline, alpha-GPC at high doses (1,200 mg) does appear to be somewhat effective in mild to moderate Alzheimer's disease and works nicely with the standard therapy (acetylcholinesterase inhibitors).
Athletes are at times interested in alpha-GPC due to its ability to enhance growth homone production (of which only acute spikes have been reported so far, so it may fall to the same problems that Arginine has on growth homone) and to enhance power output, which has a lone pilot study in support of 600 mg alpha-GPC prior to exercise. Although ergogenic properties of alpha-GPC cannot be ruled out and look promising, it requires more evidence.